Is there still a place for etomidate in the management of Cushing’s syndrome? The experience of a single center of low-dose etomidate and combined etomidate-osilodrostat treatment in severe hypercortisolemia
This study shows that low-dose and short-term lipid formulation etomidate therapy is highly effective in severe hypercortisolemia management. Combined therapy with etomidate and osilodrostat is well tolerated and could serve as a bridge in long-term SCS treatment.
Authors
- Agnieszka Wojciechowska-Luźniak (ORCID: https://orcid.org/0000-0003-1520-7752)
- Paweł Kuca (ORCID: https://orcid.org/0000-0003-2224-5554)
- Przemysław Witek (ORCID: https://orcid.org/0000-0003-4512-4624)
- Wioleta Respondek
- Łukasz Działach (ORCID: https://orcid.org/0000-0001-9283-4827)
- Joanna Sobolewska (ORCID: https://orcid.org/0000-0003-0440-2851)
Institutions
- Medical University of Warsaw (PL)
Publication Details
- Journal
- Endocrine
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1007/s12020-024-04135-1
- Citations
- 8
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.86